Abbvie Inc. (ABBV)

$150.98

-1.27

(-0.83%)▲

Live

star icon

AbbVie Inc develops and sells prescription drugs in various therapeutic areas, including immunology, oncology, and virology

Insights on Abbvie Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 12.22B → 13.86B (in $), with an average increase of 11.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 239.0M → 2.02B (in $), with an average increase of 88.2% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 65.0% return, outperforming this stock by 58.3%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 272.2% return, outperforming this stock by 197.0%

Performance

  • $150.08
    $152.19
    $150.98
    downward going graph

    0.6%

    Downside

    Day's Volatility :1.39%

    Upside

    0.8%

    downward going graph
  • $128.86
    $164.38
    $150.98
    downward going graph

    14.65%

    Downside

    52 Weeks Volatility :21.61%

    Upside

    8.15%

    downward going graph

Returns

PeriodAbbvie Inc.Sector (Health Care)S&P500
3 Months
14.28%
-1.3%
-2.2%
6 Months
-3.64%
1.8%
6.8%
1 Year
6.68%
5.6%
18.1%
3 Years
75.22%
24.9%
28.9%

Highlights

Market Capitalization
268.7B
Book Value
$7.29
Dividend Share
5.85
Dividend Yield
3.85%
Earnings Per Share (EPS)
4.86
PE Ratio
31.33
PEG Ratio
1.28
Wall Street Target Price
169.61
Profit Margin
15.5%
Operating Margin TTM
36.5%
Return On Assets TTM
9.18%
Return On Equity TTM
63.02%
Revenue TTM
56.0B
Revenue Per Share TTM
31.65
Quarterly Revenue Growth YOY
-4.9%
Gross Profit TTM
41.5B
EBITDA
29.2B
Diluted Eps TTM
4.86
Quarterly Earnings Growth YOY
1.23
EPS Estimate Current Year
11.05
EPS Estimate Next Year
11.09
EPS Estimate Current Quarter
2.81
EPS Estimate Next Quarter
2.82

Analyst Recommendation

Buy
    55%Buy
    44%Hold
    0
    0%Sell
Based on 34 Wall street analysts offering stock ratings for Abbvie Inc.(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
20
Hold
15
14
13
Sell
00
1
1

Analyst Forecast

What analysts predicted

Upside of 12.34%

Current $150.98
Target $169.61

Company Financials

FY17Y/Y Change
Revenue
28.2B
↑ 10.06%
Net Income
5.3B
↓ 10.82%
Net Profit Margin
18.82%
↓ 4.4%
FY18Y/Y Change
Revenue
32.8B
↑ 16.08%
Net Income
5.7B
↑ 7.12%
Net Profit Margin
17.36%
↓ 1.46%
FY19Y/Y Change
Revenue
33.3B
↑ 1.57%
Net Income
7.9B
↑ 38.6%
Net Profit Margin
23.69%
↑ 6.33%
FY20Y/Y Change
Revenue
45.8B
↑ 37.69%
Net Income
4.6B
↓ 41.44%
Net Profit Margin
10.08%
↓ 13.61%
FY21Y/Y Change
Revenue
56.2B
↑ 22.69%
Net Income
11.5B
↑ 150.04%
Net Profit Margin
20.54%
↑ 10.46%
FY22Y/Y Change
Revenue
58.1B
↑ 3.3%
Net Income
11.8B
↑ 2.55%
Net Profit Margin
20.39%
↓ 0.15%
Q1 FY22Q/Q Change
Revenue
13.5B
↓ 9.06%
Net Income
4.5B
↑ 11.03%
Net Profit Margin
33.17%
↑ 6.0%
Q2 FY22Q/Q Change
Revenue
14.6B
↑ 7.72%
Net Income
924.0M
↓ 79.42%
Net Profit Margin
6.34%
↓ 26.83%
Q3 FY22Q/Q Change
Revenue
14.8B
↑ 1.57%
Net Income
3.9B
↑ 327.38%
Net Profit Margin
26.66%
↑ 20.32%
Q4 FY22Q/Q Change
Revenue
15.1B
↑ 2.09%
Net Income
2.5B
↓ 37.38%
Net Profit Margin
16.35%
↓ 10.31%
Q1 FY23Q/Q Change
Revenue
12.2B
↓ 19.15%
Net Income
239.0M
↓ 90.34%
Net Profit Margin
1.96%
↓ 14.39%
Q2 FY23Q/Q Change
Revenue
13.9B
↑ 13.42%
Net Income
2.0B
↑ 746.86%
Net Profit Margin
14.6%
↑ 12.64%
FY17Y/Y Change
Total Assets
70.8B
↑ 7.09%
Total Liabilities
65.7B
↑ 6.88%
FY18Y/Y Change
Total Assets
59.4B
↓ 16.15%
Total Liabilities
67.8B
↑ 3.21%
FY19Y/Y Change
Total Assets
89.1B
↑ 50.15%
Total Liabilities
97.3B
↑ 43.5%
FY20Y/Y Change
Total Assets
150.6B
↑ 68.96%
Total Liabilities
137.5B
↑ 41.3%
FY21Y/Y Change
Total Assets
146.5B
↓ 2.68%
Total Liabilities
131.1B
↓ 4.64%
FY22Y/Y Change
Total Assets
138.8B
↓ 5.27%
Total Liabilities
121.5B
↓ 7.3%
Q1 FY22Q/Q Change
Total Assets
143.2B
↓ 2.26%
Total Liabilities
126.9B
↓ 3.2%
Q2 FY22Q/Q Change
Total Assets
143.2B
↓ 0.02%
Total Liabilities
128.5B
↑ 1.26%
Q3 FY22Q/Q Change
Total Assets
141.3B
↓ 1.3%
Total Liabilities
125.3B
↓ 2.49%
Q4 FY22Q/Q Change
Total Assets
138.8B
↓ 1.78%
Total Liabilities
121.5B
↓ 3.02%
FY17Y/Y Change
Operating Cash Flow
10.0B
↑ 41.46%
Investing Cash Flow
-274.0M
↓ 95.49%
Financing Cash Flow
-5.5B
↑ 40.33%
FY18Y/Y Change
Operating Cash Flow
13.4B
↑ 34.81%
Investing Cash Flow
-1.0B
↑ 267.15%
Financing Cash Flow
-14.4B
↑ 161.18%
FY19Y/Y Change
Operating Cash Flow
13.3B
↓ 0.77%
Investing Cash Flow
596.0M
↓ 159.24%
Financing Cash Flow
18.7B
↓ 229.95%
FY20Y/Y Change
Operating Cash Flow
17.6B
↑ 32.0%
Investing Cash Flow
-37.6B
↓ 6401.51%
Financing Cash Flow
-11.5B
↓ 161.48%
FY21Y/Y Change
Operating Cash Flow
22.8B
↑ 29.5%
Investing Cash Flow
-2.3B
↓ 93.76%
Financing Cash Flow
-19.0B
↑ 65.54%
Q1 FY22Q/Q Change
Operating Cash Flow
4.9B
↓ 3.29%
Investing Cash Flow
-1.6B
↑ 38.95%
Financing Cash Flow
-7.0B
↑ 10.0%
Q2 FY22Q/Q Change
Operating Cash Flow
5.0B
↑ 1.98%
Investing Cash Flow
130.0M
↓ 108.17%
Financing Cash Flow
-2.7B
↓ 61.57%
Q3 FY22Q/Q Change
Operating Cash Flow
7.6B
↑ 51.89%
Investing Cash Flow
1.3B
↑ 889.23%
Financing Cash Flow
-5.5B
↑ 105.97%

Technicals Summary

Sell

Neutral

Buy

Abbvie Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abbvie Inc.
Abbvie Inc.
3.16%
-3.64%
6.68%
75.22%
60.26%
Eli Lilly And Company
Eli Lilly And Company
-1.71%
62.1%
64.98%
272.25%
405.99%
Johnson & Johnson
Johnson & Johnson
-4.52%
2.33%
-4.65%
6.68%
12.31%
Merck & Co. Inc.
Merck & Co. Inc.
-5.17%
-0.59%
20.38%
27.35%
45.81%
Pfizer Inc.
Pfizer Inc.
-11.23%
-20.27%
-27.33%
-11.28%
-27.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abbvie Inc.
Abbvie Inc.
31.33
31.33
1.28
11.05
0.63
0.09
0.04
7.29
Eli Lilly And Company
Eli Lilly And Company
76.25
76.25
2.18
8.92
0.66
0.1
0.01
12.3
Johnson & Johnson
Johnson & Johnson
32.06
32.06
3.79
9.47
0.17
0.09
0.03
28.92
Merck & Co. Inc.
Merck & Co. Inc.
85.2
85.2
1.36
2.86
0.08
0.05
0.03
15.24
Pfizer Inc.
Pfizer Inc.
8.54
8.54
1.17
3.12
0.23
0.08
0.05
17.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abbvie Inc.
Abbvie Inc.
Buy
$268.7B
60.26%
31.33
15.5%
Eli Lilly And Company
Eli Lilly And Company
Buy
$521.9B
405.99%
76.25
22.01%
Johnson & Johnson
Johnson & Johnson
Hold
$378.3B
12.31%
32.06
13.35%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$263.7B
45.81%
85.2
5.34%
Pfizer Inc.
Pfizer Inc.
Hold
$181.2B
-27.51%
8.54
27.55%

Institutional Holdings

  • Vanguard Group Inc

    9.03%

  • BlackRock Inc

    7.88%

  • State Street Corporation

    4.43%

  • JPMorgan Chase & Co

    3.22%

  • Capital Research & Mgmt Co - Division 3

    2.44%

  • Geode Capital Management, LLC

    1.98%

Corporate Announcements

  • Abbvie Inc. Dividends September,2023

    In the quarter ending September,2023. Abbvie Inc. has declared dividend of $1.48

    Read More

Company Information

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Organization
Abbvie Inc.
Employees
50000
CEO
Mr. Richard A. Gonzalez
Industry
Health Technology

Discover More

FAQs